Advertisement
INCY vs LCID
Which Stock Would AI Choose? Incyte (INCY) vs. Lucid Group (LCID) Stock Comparison
Key Takeaways
- INCY (Incyte) is a profitable, cash-generative biopharmaceutical company, while LCID (Lucid Group) is a pre-profit electric-vehicle maker still burning significant cash.
- Recent market activity has favored stability: INCY has held up better on a relative-performance basis, while LCID has declined sharply over the past year.
- Incyte's near-term pressure stems from softer forward revenue guidance, whereas Lucid's volatility reflects execution, liquidity, and scaling challenges.
- The two names occupy entirely different sectors—healthcare versus consumer discretionary—so their risk profiles and catalysts are largely uncorrelated.
- Analyst sentiment leans more constructive on INCY, while LCID carries a broadly neutral-to-cautious consensus view.
- For more detail on each name, explore INCY Major News and INCY Today's Price Move, as well as LCID Major News and LCID Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
At first glance, Incyte and Lucid Group have little in common beyond their Nasdaq listings. One is an established biotechnology firm generating positive earnings from approved medicines; the other is a growth-stage electric-vehicle manufacturer still navigating heavy losses. Yet the two make an instructive stock comparison because they represent opposite ends of the risk spectrum. Income- and quality-oriented investors may find Incyte's profitable drug franchise more compelling, while speculative, growth-focused traders may be drawn to Lucid's longer-term EV (electric vehicle) and autonomy narrative. Comparing their recent performance, business models, and market positioning helps clarify which type of risk-and-reward profile aligns with a given strategy.
INCY Overview and Recent Performance
INCY, Incyte Corporation, is a biopharmaceutical company best known for its oncology and dermatology portfolio, anchored by Jakafi (ruxolitinib) and the topical cream Opzelura. The company is profitable and generates meaningful free cash flow, supported by a sizable cash position. In recent weeks, however, shares have pulled back after management issued forward revenue guidance that came in below Wall Street consensus, prompting investors to reassess near-term growth. Despite this, fourth-quarter earnings showed improvement year over year, and core products continued to post sales growth. Broader catalysts—including oncology data presentations, a July acquisition of Vega Therapeutics, and a clinical collaboration with Genmab—have kept the pipeline narrative active, even as sentiment cooled around the softer guidance.
LCID Overview and Recent Performance
LCID, Lucid Group, designs and manufactures premium electric vehicles, including the Air sedan and Gravity SUV (sport utility vehicle), while developing a mid-size platform and robotaxi partnerships with Uber and Nuro. The company remains unprofitable, with negative gross margins and sustained cash burn. Recent market activity has been challenging: shares have fallen substantially over the trailing twelve months as investors weighed repeated revenue misses, inventory write-downs, and a supplier disruption that slowed Gravity deliveries. A new chief executive, Silvio Napoli, has launched a broad operational reset focused on cost discipline, quality, and liquidity, and the company has raised capital to extend its runway. Still, execution risk and continued losses remain central to sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated showcase of automated trading strategies drawn from a much larger universe of AI trading bots. Tickeron hosts hundreds of bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and basket of tickers, so traders can compare approaches rather than settling for a one-size-fits-all system. Whether a bot leans toward momentum, swing, or longer-horizon positioning, the page surfaces strategies currently resonating with live market behavior. Investors evaluating names like INCY and LCID can explore Trending AI Robots to see how automated systems are adapting in real time.
Head-to-Head Comparison
The sharpest contrast between these two stocks is profitability. Incyte is earnings-positive and cash-generative, while Lucid continues to report steep net losses and negative gross margins. Incyte's growth is driven by drug approvals, label expansions, and pipeline progress, whereas Lucid's hinges on scaling production, lowering costs, and successfully launching a mid-size vehicle and robotaxi program. On risk factors, Incyte faces clinical, regulatory, and patent-concentration concerns around Jakafi, while Lucid faces capital-raising dilution, supply-chain constraints, and uncertain EV demand. From a sentiment standpoint, INCY has retained more constructive analyst coverage, with several firms maintaining buy ratings, while LCID has seen price targets cut amid a consensus "Hold" rating. In short, Incyte offers established fundamentals with moderate pipeline risk; Lucid offers optionality on EV and autonomy growth with materially higher execution and liquidity risk.
Tickeron AI Verdict
Based on observable factors—trend consistency, earnings stability, cash generation, and relative market positioning—Tickeron's AI would likely favor INCY over LCID in the current environment. Incyte's profitable base business, healthy balance sheet, and more stable price structure present a steadier trend profile than Lucid's ongoing losses, negative margins, and elevated volatility. That said, this is a probabilistic assessment rooted in risk-adjusted positioning rather than a forecast of absolute returns; Lucid's turnaround and mid-size platform could still create catalysts that shift relative momentum. The AI's edge, on balance, skews toward the company with more consistent fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and LCID is a Hold.
INCY's RSI Oscillator ascends from oversold territory
The RSI Oscillator for INCY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 22 of the 34 cases the stock moved higher. This puts the odds of a move higher at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 59 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 21 of 35 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 208 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.697) is normal, around the industry mean (3.035). P/E Ratio (14.232) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (438.009).
LCID's RSI Oscillator ascends from oversold territory
The RSI Indicator for LCID moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 36 of the 43 cases the stock moved higher. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 72 cases where LCID's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for LCID just turned positive on October 22, 2026. Looking at past instances where LCID's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.
Following a +9.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCID advanced for three days, in 189 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
LCID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCID as a result. In 86 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LCID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.311) is normal, around the industry mean (1.864). P/E Ratio (-0.257) is within average values for comparable stocks, (13.557). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.450). Dividend Yield (0.000) settles around the average of (0.160) among similar stocks. P/S Ratio (0.883) is also within normal values, averaging (2.648).
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. LCID’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
INCY | LCID | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 35 | 100 | |
SMR RATING 1..100 | 33 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 87 | |
P/E GROWTH RATING 1..100 | 79 | 9 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LCID's Valuation (9) in the null industry is significantly better than the same rating for INCY (92) in the Biotechnology industry. This means that LCID’s stock grew significantly faster than INCY’s over the last 12 months.
INCY's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for LCID (100) in the null industry. This means that INCY’s stock grew somewhat faster than LCID’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is significantly better than the same rating for LCID (100) in the null industry. This means that INCY’s stock grew significantly faster than LCID’s over the last 12 months.
INCY's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for LCID (87) in the null industry. This means that INCY’s stock grew somewhat faster than LCID’s over the last 12 months.
LCID's P/E Growth Rating (9) in the null industry is significantly better than the same rating for INCY (79) in the Biotechnology industry. This means that LCID’s stock grew significantly faster than INCY’s over the last 12 months.
| INCY | LCID | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 90% |
| Advances ODDS (%) | 5 days ago 64% | 2 days ago 77% |
| Declines ODDS (%) | 12 days ago 55% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green while LCID’s FA Score has 2 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- LCID’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while LCID’s TA Score has 5 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 5 bearish.
- LCID’s TA Score: 5 bullish, 3 bearish.
Price Growth
INCY (@Biotechnology) experienced а +2.33% price change this week, while LCID (@Motor Vehicles) price change was +12.46% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
The average weekly price growth across all stocks in the @Motor Vehicles industry was -6.02%. For the same industry, the average monthly price growth was -18.16%, and the average quarterly price growth was -33.78%.
Reported Earning Dates
INCY is expected to report earnings on Oct 29, 2026.
LCID is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Motor Vehicles (-6.02% weekly)Automobiles continue to be arguably the most popular form of passenger travel in the U.S., and major automobile makers have revenues and market capitalizations running into multi-billions. In recent years, the industry has been experiencing some path-breaking innovations like electric vehicles and self-driving technology. While there are long-standing companies like General Motors, Ford, and Toyota Motors operating in this space, there are also emerging/rapidly growing players like Tesla – which has had a major role in the growing popularity of the electric vehicle market. With technological advancements taking steam in the auto space, we’ve also witnessed collaborations (or talks of potential partnerships) of carmakers with tech behemoths like Google’s subsidiary, Waymo.
Advertisement